Mohammadi Amin, Goharimehr Mahshad, Darvishi Ali, Heshmat Ramin, Esfahani Ensieh Nasli, Shafiee Gita, Ostovar Afshin, Daroudi Rajabali
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
National Center for Health Insurance Research, Tehran, Iran.
BMC Public Health. 2025 Jan 4;25(1):35. doi: 10.1186/s12889-024-21247-5.
Diabetes mellitus, particularly Type 2 diabetes (T2D), represents a significant global health challenge, with its prevalence steadily rising over the past few decades. This study was conducted with the aim of estimating the economic burden of T2D in Iran.
This study employed a prevalence-based approach to estimate the economic burden of T2D and its attributable complications in adults above 20 years old in Iran for 2022. Both direct medical costs and indirect costs were considered in our analysis. Direct medical costs included inpatient and outpatient costs attributable to T2D and its complications, while indirect costs encompassed absenteeism, presenteeism, inability to work, and premature mortality costs due to the disease.
The findings showed that a total of 5,702,547 people, equivalent to 14.2% of Iranian adults, had T2D. The estimated total direct medical cost of T2D and its attributable complications in Iran in 2022 was 1,879.2 million US dollars (US$-PPP 6,676.9 million). Chronic kidney disease accounted for the largest proportion, followed by ischemic heart disease (IHD), and T2D itself. The total economic burden of T2D and its attributable complications in Iran in 2022, was estimated to be $2,905.7 million US dollars (US$-PPP 10,324.2 million). The direct medical cost constituted the majority of the economic burden (64.7%), while the inability to work due to these health conditions also contributes significantly (28.6%). Absenteeism (2.9%), presenteeism (1.7%), and premature mortality (2.2%) make up smaller proportions of the overall economic impact of T2D and its complications in Iran during that year.
Our study highlights the significant and diverse economic impact of T2D and its complications in Iran. This burden encompasses not only healthcare-related expenses but also negative impacts on society and productivity, as well as the occurrence of early death. To successfully address this burden, a comprehensive strategy is needed, which includes programs to prevent diabetes, better access to healthcare services, and increased social support for individuals with this long-term condition.
糖尿病，尤其是2型糖尿病（T2D），是一项重大的全球健康挑战，在过去几十年中其患病率稳步上升。本研究旨在估算伊朗2型糖尿病的经济负担。
本研究采用基于患病率的方法，估算2022年伊朗20岁以上成年人中2型糖尿病及其所致并发症的经济负担。我们的分析中同时考虑了直接医疗成本和间接成本。直接医疗成本包括2型糖尿病及其并发症的住院和门诊费用，而间接成本包括旷工、出勤主义、无法工作以及因该疾病导致的过早死亡成本。
研究结果显示，共有5,702,547人患有2型糖尿病，相当于伊朗成年人的14.2%。2022年伊朗2型糖尿病及其所致并发症的估计直接医疗总成本为18.792亿美元（按购买力平价计算为66.769亿美元）。慢性肾脏病占比最大，其次是缺血性心脏病（IHD）和2型糖尿病本身。2022年伊朗2型糖尿病及其所致并发症的总经济负担估计为29.057亿美元（按购买力平价计算为103.242亿美元）。直接医疗成本占经济负担的大部分（64.7%），而由于这些健康状况导致无法工作也占很大比例（28.6%）。旷工（2.9%）、出勤主义（1.7%）和过早死亡（2.2%）在该年伊朗2型糖尿病及其并发症的总体经济影响中占比更小。
我们的研究突出了2型糖尿病及其并发症在伊朗造成的重大且多样的经济影响。这种负担不仅包括与医疗保健相关的费用，还包括对社会和生产力的负面影响以及过早死亡的发生。为了成功应对这一负担，需要一项全面的战略，其中包括预防糖尿病的计划、更好地获得医疗服务以及增加对患有这种慢性病的个人的社会支持。
